The study is designed to compare the effects of two combination of nutraceuticals: Armolipid
Plus® and LopiGLIK® (Akademy Pharma), a new supplement that, in addition to Berberine and Red
Rice, contains Morus Alba's extract. The study will analyze the impact of 16 week treatment
with one of the combinations, according to a randomized scheme, on metabolic parameters in
dyslipidemic subjects that do not require or not tolerate a statin therapy. In particular, it
will assess the ability of the two combinations to reduce the levels of total and LDL
cholesterol, HbA1C, glicaemia and insulin and increase those of HDL cholesterol.